The role of miRNAs and lncRNAs in neurofibromatosis type 1

被引:6
|
作者
Khosravi, Teymoor [1 ]
Oladnabi, Morteza [2 ,3 ,4 ]
机构
[1] Golestan Univ Med Sci, Student Res Comm, Gorgan, Iran
[2] Golestan Univ Med Sci, Gorgan Congenital Malformat Res Ctr, Gorgan, Iran
[3] Golestan Univ Med Sci, Ischem Disorders Res Ctr, Gorgan, Iran
[4] Golestan Univ Med Sci, Sch Adv Technol Med, Dept Med Genet, Gorgan 4916978342, Iran
关键词
long noncoding RNA; mircoRNAs; neurofibromatosis type 1; tumourigenesis; NERVE SHEATH TUMORS; ENDOTHELIAL GROWTH-FACTOR; NF1; GENE; MICRORNA; 135; EXPRESSION; TUMORIGENESIS; MUTATIONS; GENOTYPE; BIOGENESIS; REPRESSION;
D O I
10.1002/jcb.30349
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurofibromatosis Type 1 (NF1) is a frequent cancer predisposition syndrome. The common hallmark of patients with this multisystemic genetic disorder is the formation of peripheral nerve sheath tumors, which can be seen as either dermal, plexiform, and malignant forms. MicroRNA (miRNA) is an essential gene regulation factor and consists of 22-25 nucleotides. MiRNAs are identified to act as both tumor suppressors and oncogenes (oncomirs) in a wide variety of human cancers. They play multiple roles in molecular pathways responsible for tumor homing, progression, and invasion. Long noncoding RNA (lncRNA) also has a key role in cancer transcriptomics. Altered lncRNA expression levels have been found in various malignancies. This review aims to summarize the role of two noncoding RNA groups, miRNAs and lncRNAs, in NF1 establishment, development, and progression. We also highlight their potential for future clinical interventions and devising new diagnostic tools.
引用
收藏
页码:17 / 30
页数:14
相关论文
共 50 条
  • [41] 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis
    Fisher, Michael J.
    Belzberg, Allan J.
    de Blank, Peter
    De Raedt, Thomas
    Elefteriou, Florent
    Ferner, Rosalie E.
    Giovannini, Marco
    Harris, Gordon J.
    Kalamarides, Michel
    Karajannis, Matthias A.
    Kim, AeRang
    Lazaro, Conxi
    Le, Lu Q.
    Li, Wei
    Listernick, Robert
    Martin, Staci
    Morrison, Helen
    Pasmant, Eric
    Ratner, Nancy
    Schorry, Elisabeth
    Ullrich, Nicole J.
    Viskochil, David
    Weiss, Brian
    Widemann, Brigitte C.
    Zhu, Yuan
    Bakker, Annette
    Serra, Eduard
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2018, 176 (05) : 1258 - 1269
  • [42] Tumor and Constitutional Sequencing for Neurofibromatosis Type 1
    Tong, Schuyler
    Devine, W. Patrick
    Shieh, Joseph T.
    JCO PRECISION ONCOLOGY, 2022, 6
  • [43] Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1
    Monroe, Courtney L.
    Dahiya, Sonika
    Gutmann, David H.
    ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 12, 2017, 12 : 53 - 74
  • [44] Emerging therapeutic targets for neurofibromatosis type 1
    Walker, James A.
    Upadhyaya, Meena
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (05) : 419 - 437
  • [45] Molecular diagnosis strategies in neurofibromatosis type 1
    Bhouri, R.
    Hebrard, B.
    Wolkenstein, P.
    Funalot, B.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2020, 147 (03): : 247 - 251
  • [46] miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
    Di Martino, Maria Teresa
    Riillo, Caterina
    Scionti, Francesca
    Grillone, Katia
    Polera, Nicoletta
    Caracciolo, Daniele
    Arbitrio, Mariamena
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    CANCERS, 2021, 13 (07)
  • [47] Immune markers in the RASopathy neurofibromatosis type 1
    Torres, Karen C. L.
    Lima, Giselle
    Simoes e Silva, Ana C.
    Lubambo, Isabela
    Rodrigues, Luiz O.
    Rodrigues, Luiza
    Silveira, Katia D.
    Vieira, Erica L. M.
    Romano-Silva, Marco A.
    Miranda, Debora M.
    JOURNAL OF NEUROIMMUNOLOGY, 2016, 295 : 122 - 129
  • [48] Neurofibromatosis type 1: from genotype to phenotype
    Pasmant, Eric
    Vidaud, Michel
    Vidaud, Dominique
    Wolkenstein, Pierre
    JOURNAL OF MEDICAL GENETICS, 2012, 49 (08) : 483 - 489
  • [49] Non-Coding RNA and Tumor Development in Neurofibromatosis Type 1: ANRIL Rs2151280 Is Associated with Optic Glioma Development and a Mild Phenotype in Neurofibromatosis Type 1 Patients
    Tritto, Viviana
    Ferrari, Luca
    Esposito, Silvia
    Zuccotti, Paola
    Bianchessi, Donatella
    Natacci, Federica
    Saletti, Veronica
    Eoli, Marica
    Riva, Paola
    GENES, 2019, 10 (11)
  • [50] A Review of Spinal Lesions in Neurofibromatosis Type 1 in a Large Neurofibromatosis Type 1 Center
    Sial, Moska
    George, K. Joshi
    WORLD NEUROSURGERY, 2023, 169 : E157 - E163